XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)
$ / shares in Units, shares in Thousands, € in Millions, $ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 16, 2020
USD ($)
Apr. 01, 2019
USD ($)
Nov. 30, 2020
USD ($)
Oct. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
EUR (€)
Jul. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
May 31, 2020
USD ($)
Jul. 31, 2019
USD ($)
Apr. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration         $ 829.0             $ 829.0 $ 755.0 $ 829.0 $ 755.0 $ 767.0 $ 788.0
Goodwill         20,248.0             20,248.0   20,248.0   19,425.0  
Research and development                       3,390.0 3,204.0 7,721.0 7,324.0    
Inventories         6,128.0             6,128.0   6,128.0   $ 5,978.0  
Payments to Acquire Productive Assets                           3,170.0 2,336.0    
Forward Contracts | Research and development                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Amount of Derivative Pretax (Gain) Loss Recognized in Income                       (22.0) $ 0.0 (22.0) $ 0.0    
Forward Contracts | Research and development | Subsequent Event                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Amount of Derivative Pretax (Gain) Loss Recognized in Income       $ 6.0                          
Sentinel                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business             $ 410.0                    
Dunboyne                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Other assets and liabilities, net         13.0             13.0   13.0      
Payments to Acquire Productive Assets         302.0 € 256                      
Property, plant and equipment         289.0             $ 289.0   $ 289.0      
Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business               $ 366.0                  
Contingent consideration, maximum               740.0                  
Contingent consideration               97.0                  
IPR&D               136.0                  
Cash and cash equivalents               59.0                  
Goodwill               229.0                  
Deferred tax assets               71.0                  
Other assets and liabilities, net               (32.0)                  
ArQule                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business $ 2,700.0                                
IPR&D 2,280.0                                
Share-based compensation payments attributable to precombination service 138.0                                
Transaction costs 95.0                                
Cash and cash equivalents 145.0                                
Goodwill 540.0                                
Other assets and liabilities, net 34.0                                
Deferred income tax liabilities 389.0                                
Intangible assets $ 80.0                                
Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business                   $ 1,200.0              
Cash and cash equivalents                   157.0              
Other assets and liabilities, net                   6.0              
Research and development                   982.0              
Deferred income tax liabilities                   64.0              
Antelliq                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business   $ 2,300.0                              
Transaction costs   47.0                              
Cash and cash equivalents   31.0                              
Goodwill   1,376.0                              
Debt assumed and paid   1,300.0                              
Other assets and liabilities, net   (82.0)                              
Deferred income tax liabilities   589.0                              
Inventories   93.0                              
Intangible assets   2,689.0                              
Property, plant and equipment   $ 60.0                              
Immune Design                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business                     $ 301.0            
IPR&D                     156.0            
Cash and cash equivalents                     83.0            
Other net assets                     42.0            
Goodwill                     $ 20.0            
VelosBio [Member] | Forecast                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business     $ 2,750.0                            
Development Milestones | Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum               80.0                  
Sales-Based Milestones | Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum               400.0                  
Sales-Based Milestones | Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum                   1,050.0              
Regulatory Milestones | Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum               $ 260.0                  
Regulatory Milestones | Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum                   50.0              
Commercial Milestone | Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum                   $ 50.0              
Seagen                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments         $ 600.0                        
Share price (in dollars per share) | $ / shares         $ 200             $ 200   $ 200      
Contingent milestone payments collaborative arrangement         $ 2,600.0                        
Payments to Acquire Investments         1,000.0                        
Research and development         $ 622.0                        
Forward contract, shares | shares         5,000             5,000   5,000      
Seagen | Tukysa                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments         $ 210.0                        
Seagen | Tukysa | Minimum                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Royalty Rate, Percentage         20.00% 20.00%                      
Seagen | Tukysa | Maximum                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Royalty Rate, Percentage         33.00% 33.00%                      
Seagen | Sales-Based Milestones                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent milestone payments collaborative arrangement         $ 1,750.0                        
Seagen | Regulatory Milestones                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent milestone payments collaborative arrangement         850.0                        
Seagen | Regulatory Milestones | Tukysa                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent milestone payments collaborative arrangement         $ 65.0                        
IAVI                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments                 $ 6.5                
Contingent milestone payments collaborative arrangement                 $ 100.0                
Technology Rights | Sentinel                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Acquired rights             401.0                    
Inventories             $ 9.0